Abivax appoints Alexandra Pearce as VP of Regulatory Affairs

Abivax, has announced the appointment of Dr. Alexandra Pearce as Vice President and Head of Regulatory Affairs, effective May 21, 2018. Dr. Pearce brings to ABIVAX broad experience in regulatory affairs and in working closely with the U.S. Food and Drug Administration (FDA) and with the European Medicines Agency (EMA). She has successfully led the global regulatory process through approval across a variety of therapeutic areas.

Dr. Pearce joins ABIVAX from Viramal, where she served as Chief Operations Officer and Head of Regulatory Affairs. Previously, she held roles as Executive Vice President and Head of Global Regulatory Affairs for Glenmark (UK), responsible for regulatory strategy, drug development and the successful commercialization of all in-house and in-licensed products spanning 80 countries. Prior to this, as Executive Director, Global Regulatory Affairs and Safety at Amgen, she was responsible for developing and executing global regulatory strategies for early pipeline molecules across all therapeutic areas. Before joining Amgen, Dr. Pearce was the Global Regulatory Leader and Director of Worldwide Regulatory Strategy at Pfizer.  In this role, Dr. Pearce was accountable for current and emerging business interests for products within the cardiovascular portfolio, as well as serving as Pfizer’s regulatory liaison with the FDA. She started her career as a research scientist at the Centre for Applied Microbiology and Research (CAMR) – Division of Biotechnology in the UK in the late 1980s, and received her Ph.D. in Biotechnology from the Open University in London in 1993.